Alnylam Pharmaceuticals (ALNY) Notes Payables (2024 - 2025)
Alnylam Pharmaceuticals' (ALNY) quarterly Notes Payables came in at $121.3 million in Q3 2025, little changed on a QoQ basis from $120.8 million in Q2 2025.
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) Notes Payables (2024 - 2025) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 2 years of Notes Payables data on file, last reported at $121.3 million in Q3 2025.
- Quarterly Notes Payables changed N/A year-over-year to $121.3 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $121.3 million (changed N/A YoY) and the FY2024 annual result came in at $93.8 million, changed N/A from the prior year.
- Notes Payables steadied at $121.3 million in Q3 2025, from $120.8 million in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $121.3 million in Q3 2025 to a low of $93.8 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 121.30 Mn |
| Jun 30, 2025 | 120.80 Mn |
| Mar 31, 2025 | 118.10 Mn |
| Dec 31, 2024 | 93.80 Mn |